Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer’s disease mouse model: A Comparative study with donepezil.
Running Title: I2 Imidazoline receptor modulation as a potential therapeutic strategy against Alzheimer’s Disease.
Foteini Vasilopoulou1, Sergio Rodríguez-Arévalo2, Andrea Bagán2, Carmen Escolano2, Christian Griñán-Ferré1* and Mercè Pallàs1*
1Pharmacology Section. Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain.
2Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain.